Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis

Hepatology

Volumn 38, Issue 4, 2003, Pages 999-1007

  Pérez Carreras, Mercedes ^a   Del Hoyo, Pilar ^a   Martín, Miguel A ^a   Rubio, Juan C ^a   Martín, Ana ^a   Castellano, Gregorio ^a   Colina, Francisco ^a   Arenas, Joaquín ^a   Solis Herruzo, José A ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; CARNITINE; FATTY ACID; LONG CHAIN ACYLCARNITINE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SHORT CHAIN ACYLCARNITINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID TRANSPORT; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HOMEOSTATIC METABOLIC ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER MITOCHONDRION; MALE; MITOCHONDRIAL RESPIRATION; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY CHAIN; SCORING SYSTEM;

EID: 18144444592     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50398     Document Type: Article

References (48)

1. Ludwig J, Viggiano RT, McGill DB. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:342-348.
2. Matteoni CA, Younossi ZM, Gramlich T, Boparal N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
3. Brunt EM, Janney CG, Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
4. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. HEPATOLOGY 2002;35:746-752.
5. Chittury S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
6. James O, Day CP. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 1999;353:1634-1636.
7. Berson A, De Beco V, Lettéron P, Robin MA, Moreau C, Kahwaji J, Verthier N, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998; 114:764-774.
8. Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steato-hepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol 1997;26:13-22.
9. Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steato-hepatitis V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol 2002;282:G193-G199.
10. Morris A. Mitochondrial respiratory chain disorders and the liver. Liver 1999;19:357-368.
11. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 1994;344:721-724.
12. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-274.
13. Gerber MA, Popper H. Relation between central canals and portal tracts in alcoholic hepatitis. A contribution to pathogenesis of cirrhosis in alcoholics. Hum Pathol 1972;3:199-207.
14. Di Donato S, Rimoldi M, Garavaglia B, Uziel G. Propionil carnitine excretion in propionic and methylmalonic acidurias: a cause of carnitine deficiency. Clin Chim Acta 1984;139:13-21.
15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-271.
16. Di Mauro S, Di Mauro PM. Muscle carnitine palmityl transferase deficiency and myoglobinuria. Science 1973;182:929-931.
17. Martinez B, Del Hoyos P, Martin MA, Arenas J, Perez-Castillo A, Santos A. Thyroid hormone regulates oxidative phosphorylation in the cerebral cortex and striatum of neonatal rats. J Neurochemistry 2001;78:1054-1063.
18. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999;341:427-434.
19. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio heart study. Diabetes Care 1997;20:1087-1092.
20. Bremer J. Carnitine: metabolism and functions. Physiol Rev 1983;63: 1420-1480.
21. Bowyer BA, Miles JM, Haymond MW, Fleming CR. L-Carnitine therapy in home parenteral nutrition patients with abnormal liver tests and low plasma carnitine concentration. Gastroenterology 1988;94:434-438.
22. Kräenbühl S, Mang G, Kupferschmidt H, Meier PJ, Krause M. Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity. Gut 1995;37:140-143.
23. Harper P, Wadström C, Backman L, Cederblad G. Increased liver carnitine content in obese women. Am J Clin Nutr 1995;61:18-25.
24. De Sousa C, Leung NWY, Chalmers RA, Peters TJ. Free and total carnitine and acylcarnitine content of plasma, urine, liver and muscle of alcoholics. Clin Sci 1988;75:437-440.
25. Campos Y, Huertas R, Lorenzo G, Bautista J, Gutiérrez E, Aparicio M, Alesso L, et al. Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 1993;16:150-153.
26. Fréneaux E, Labbe G, Lettéron P, Le Dinh T, Deggot C, Genéve J, Larey D, et al. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. HEPATOLOGY 1988;8:1056-1062.
27. Deschamps D, De Beco V, Fisch C, Fromenty B, Guillouzo A, Pessayre D. Inhibition by perhexiline of oxidative phosphorylation and the β-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. HEPATOLOGY 1994;19:948-961.
28. Tyr) causing the "hepatic" form of carnitine palmitoyltransferase II deficiency. Hum Genet 1996;98:116-118.
29. Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, Parker WD Jr. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999;31:430-434.
30. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
31. Haque M, Mirshahi F, Campbell-Sargent C, Sterling RK, Luketic VA, Shiffman ML, Stravitz RT, et al. Nonalcoholic steatohepatitis (NASH) is associated with hepatocyte mitochondrial depletion [Abstract]. HEPATOLOGY 2002;36:430A.
32. Lancaster JR, Laster SM, Gooding LR. Inhibition of target cell mitochondrial electron transfer by tumor necrosis factor. FEBS Lett 1989;248:169-174.
33. Higuchi M, Proske RJ, Yeh ET. Inhibition of mitochondrial respiratory chain complex I by TNF results in cytochrome c release, membrane permeability transition, and apoptosis. Oncogene 1998;17:2515-2524.
34. Sanchez-Alcazar JA, Schneider E, Martinez MA, Carmona P, Hernandez-Munoz I, Siles E, De la Torre P, et al. Tumor necrosis factor-α increases the steady state reduction of cytochrome b of the mitochondrial respiratory chain in metabolically inhibited L929 cells. J Biol Chem 2000;275:13353-13361.
35. Wallace DC. Mitochondrial disease in man and mouse. Science 1999;283: 1482-1488.
36. Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995;67:101-154.
37. Cadet J, Delatour T, Douki T, Gasparutto D, Pouget JP, Ravanat JL, Sauvaigo S. Hydroxyl radicals and DNA base damage. Mutat Res 1999; 424:9-21.
38. Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. The effect of reactive oxygen species generated from the mitochondrial electron transport chain on the cytochrome c oxidase activity and on the cardiolipin content in bovine heart submitochondrial particles. FEBS Lett 2000;466:323-326.
39. Ide T, Tsutsui H, Hayashidani S, Kang D, Suematsu N, Nakamura K, Utsumi H, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 2001;88:529-535.
40. Crespo J, Cayón A, Fernández-Gil P, Herná ndez-Guerra M, Mayorga M, Domínguez-Díaz A, Ferná ndez-Escalante JC, et al. Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. HEPATOLOGY 2001;34:1158-1163.
41. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-1476.
42. Zeviani M, Tiranti V, Piantadosi C. Mitochondrial disorders. Medicine 1998;77:59-72.
43. Collins AR. Oxidative DNA damage, antioxidants, and cancer. Bioessays 1999;21:238-246.
44. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor alpha: direct role in obesity linked insulin resistance. Science 1993;259:87-91.
45. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-2119.
46. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55TNF receptor and activation of sphingomyelinase. J Biol Chem 1996;271:13018-13022.
47. Teoman Uysal K, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNFα function. Nature 1997;389:610-614.
48. Li Z, Peraldi P, Yang S, Lin H, Huang J, Watkins PA, Moster AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. HEPATOLOGY 2003;37:343-350.